Highlights of this issue
(1) Cognitive function supplements have become mainstream, what are the trends in 2022?
(2) The development trend of sleep health care products industry in 2022
(3) 5 major nutrients, or will help you faster, higher, stronger
(4) Bioniq acquires LOEWI, a personalized nutrition company
(5) Altimmune's new obesity drug Pemvidutide entered Phase 2 clinical trials
Author: Jennifer Grebow
Interpretation: Richard
Source: Nutritional OUTLOOK
Release date: 2022/01/22
■ Content points
Out of concern for their own health problems, consumers have begun to actively care about the health of their cognitive functions such as memory, concentration and psychological endurance. The field of cognitive function consumption has ushered in growth, not only the elderly population has put the maintenance of cognitive function first, but also the younger population has begun to seek to use supplements to maintain brain health. What are the trends in cognitive function supplements in 2022?
Strong sales of cognitive health products: Overall sales of cognitive health products increased by 59% in the mainstream U.S. supplement market, with half of both physical stores and e-commerce channels. Consumers tend to choose products that they approve of.
Significant growth in multivitamins: Multivitamins have been the biggest player in the supplement product space, with sales of products for women's cognitive health growing by 99 percent and male users up 186 percent. The multi-health benefits of multivitamins are the number one factor in attracting consumers.
Phosphatidylserine (PS) performed impressively: PS saw strong growth in cognitive health functional ingredients, with PS sales up 91% in 2021. The health effects of PS in maintaining cognitive function have been demonstrated in clinical trials, and its beneficial effects on athletic performance and skin health have also received attention.
Recognition of plant-based ingredients: Mushrooms, bacopa monnieri and other plant-based ingredients that contribute to cognitive health will continue to grow in the market in 2021.
There is room for growth, but the growth rate may slow down: Cognitive health supplements are still in their infancy, accounting for about 3% of total dietary supplement sales, and they will undoubtedly continue to sell well in 2022, but the growth prospects are unclear after that, and the growth rate may slow down.
Original link:
https://www.nutritionaloutlook.com/view/aidp-inc-to-distribute-the-ultimine-brand-of-whole-food-minerals-made-by-cura-global-health-inc-
By Jennifer Grebow
Interpretation: Ninety
Source: Nutritional Outlook
Release date: 1/31/2022
Sleep is seen as an integral part of overall health. Consumers will continue to focus on sleep solutions in 2021. So, what are the current trends in the sleep supplement market?
Consumers are highly concerned about sleep problems: A 2021 consumer sleep survey showed that sleep problems are the top concern for many Americans, with 50 percent believing that improving sleep is the top mental health goal in 2021. Nearly 40 percent of respondents said sleep problems have a negative impact on their personal lives.
Sleep supplements are popular: As of September 2021, sales of sleep-supporting supplements on Amazon increased by 55% year-on-year; 82% of U.S. consumers expressed interest in vitamins and supplements that improve sleep quality; and about 48% of young people adopted vitamins, minerals and supplements for self-care.
Melatonin has grown significantly, as have other sleep-assisting ingredients: Melatonin, the main functional component of sleep products, has seen significant market share growth in mainstream and natural supplement channels in the United States and even outside the sleep market. In addition, many non-melatonin ingredients, such as L-theanine, chamomile, lemon balm, magnesium and 5-HTP, also performed well.
Consumers are demanding new sleep-assisting products: Consumers are demanding a variety of delivery forms, and manufacturers need to manufacture sleep support products in different dosage forms, such as gummies, tablets, capsules, etc. In addition, solutions with multiple health benefits are more popular with consumers.
https://www.nutritionaloutlook.com/view/sleep-support-surges-in-2022-2022-ingredient-trends-for-food-drinks-dietary-supplements-and-natural-products
By Gene Bruno
Interpretation: Xiong Qingqing
Release date: 2022/01/26
The global sports nutrition market, valued at $15.6 billion in 2019, is expected to grow at a CAGR of 8.9% from 2020 to 2027. As young people move towards healthy lifestyles, more and more people are participating in sports, and there is an increasing demand for products that accelerate recovery and improve athletic performance.
1. Ashwagandha extract: an adaptable herb that can increase testosterone levels in men by 15%-17%, increase muscle size and strength, reduce body fat rate, and improve cardiopulmonary endurance. According to Databridge Market Research, the global Ashwagandha extract market is expected to reach $102.72 million by 2029, representing a CAGR of 11.4%.
2. Quercetin Phospholipid Complex: This ingredient can be better absorbed than quercetin, which can significantly improve running speed, improve muscle pain, cramps, local pain after running and reduce recovery time after exercise. According to SpentEdge, the global quercetin extract market is expected to reach $110.8 million by 2024, representing a CAGR of 6.53%.
3. Tart Cherry Extract: A polyphenol compound containing antioxidant and anti-inflammatory that improves the recovery of muscle strength, reduces muscle damage, strengthens exercise recovery, promotes faster recovery after exercise, and improves antioxidant stress. The global dried tart cherry market is expected to reach $313 million by 2027, a CAGR of 4.5%, according to ReportLinker.
4. β-Caryophyllene: Extracted from pepper oil, it relieves pain and inflammation. It significantly reduces pain, reduces delayed muscle soreness, improves recovery, and has a good safety profile.
5. Bacillus subtilis: Is a probiotic spore-formed, which can survive after passing through the stomach. In addition to the benefits for immunity, digestion, and gut health, studies have shown that the bacterium can improve physical performance, reduce exercise-related inflammation, and enhance strength. According to Kingpin Market Research, the global Bacillus subtilis market is expected to reach $104.8 million by 2026, representing a CAGR of 8.7%.
https://www.nutritionaloutlook.com/view/5-must-have-ingredients-for-your-sports-supplement-product-line
By James Cook
Source: Business Leader
Recently, the British health technology company Boniq announced the acquisition of LOEWI, a personalized nutrition company incubated by the Technical University of Munich. The acquisition is intended to boost Boniq's global expansion and accelerate its operations in the European countries of Germany, Austria, Switzerland and the Netherlands, with undisclosed transaction value.
LOEWI was founded in 2018 with the goal of making personalized nutrition accessible to everyone. Its proprietary personalization tools can create tailored nutritional recommendations and supplements to improve their health by analyzing their customers' health data. The company has built a proprietary database of more than 15,000 scientific studies, incorporating more than 9,000 interactions between diseases, drugs and allergies.
LOEWI's customers include players from the German national football team, athletes from the Tour de France and the German ski national team.
Bioniq, a health support platform that offers personalized science and data-based solutions, was founded by former German national team basketball player Vadim Fedotov and neurosurgeon Dr. Konstantin Karuzin, who has 14 years of clinical research experience. Bioniq operates in the UK, UAE and Russia, providing customers with personalized solutions to optimise their health.
https://www.kdocs.cn/office/link?target=https%3A%2F%2Fwww.businessleader.co.uk%2Fuk-healthtech-company-bioniq-acquires-loewi%2F
By Hannah Chudleigh
Source: Biospace
Release date: 01/31/2022
On January 31, British biopharmaceutical company Altimmune announced that the US Food and Drug Administration (FDA) has approved a Phase 2 clinical trial of its obesity treatment drug pemvidutide.
Pemvidutide is a polypeptide-based glucagon-like peptide-1 (GLP-1)/glucagon bi-receptor agonist. Glucagon is able to increase energy expenditure and promotes the conversion of white fat in the body that stores energy into brown fat that consumes energy. It has a synergistic effect with GLP-1 and is more effective in weight loss than GLP-1 receptor agonist monotherapy.
The results of the previously published Phase 1 study showed that subcutaneous injection of 1.8 mg of pemvidutide per week for 12 weeks significantly reduced the weight, liver fat and serum lipids of overweight and obese subjects.
The Phase 2 trial will enroll approximately 320 subjects with obesity or overweight people with at least one obesity-related complication. Subjects will be injected with 1.2 mg, 1.8 mg or 2.4 mg of pemvidutide or placebo per week for 48 weeks. The study is expected to begin in the first quarter of 2022 and the results of the trial are made public by the fourth quarter of 2022.
In addition to obesity, permvidutide clinical trials for non-alcoholic fatty liver disease are also active.
https://www.kdocs.cn/office/link?target=https%3A%2F%2Fwww.biospace.com%2Farticle%2Fpotential-new-obesity-drug-heads-to-phase-ii-trials-%2F